Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Peripheral Neuropathy Due to Leprosy.

Sharon P. Nations1, Richard J. Barohn

  • 1*Department of Neurology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8897, USA. sharon.nations@utsouthwestern.edu

Current Treatment Options in Neurology
|April 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Painful Peripheral Neuropathy.

Current treatment options in neurology·2002
Same author

Peripheral Neuropathy Due to Cobalamin Deficiency.

Current treatment options in neurology·2002
Same author

Thymectomy for Myasthenia Gravis.

Current treatment options in neurology·2002
Same author

Diabetic Lumbosacral Polyradiculoneuropathies.

Current treatment options in neurology·2001
Same journal

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same journal

Non-Cognitive Symptoms in Alzheimer's Disease and Their Likely Impact on Patient Outcomes. A Scoping Review.

Current treatment options in neurology·2026
Same journal

Update on the Treatment of Autonomic Disorders.

Current treatment options in neurology·2025
Same journal

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology·2025
Same journal

Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Current treatment options in neurology·2025
Same journal

Diagnosis and Management of Progressive Corticobasal Syndrome.

Current treatment options in neurology·2025
See all related articles

Leprosy (Hansen's disease) prevalence decreased significantly with multidrug therapy. However, stable incidence persists due to asymptomatic carriers, necessitating ongoing patient monitoring for nerve damage and disability prevention.

Area of Science:

  • Infectious Diseases
  • Neurology
  • Public Health

Background:

  • Leprosy, or Hansen's disease, is a major global cause of disability.
  • Multidrug therapy (MDT) involving dapsone, rifampin, and clofazimine dramatically reduced leprosy prevalence.
  • Stable incidence rates suggest persistent transmission, possibly from asymptomatic carriers.

Purpose of the Study:

  • To summarize the impact of MDT on leprosy prevalence.
  • To highlight the ongoing challenge of new case incidence.
  • To emphasize the importance of managing nerve damage and preventing disability.

Main Methods:

  • Analysis of historical leprosy prevalence data.
  • Review of factors contributing to stable incidence rates.
  • Discussion of post-treatment complications and management strategies.

Related Experiment Videos

Main Results:

  • Leprosy prevalence fell from 5.4 million in 1985 to under 1 million by 1999 due to MDT.
  • New leprosy case incidence remains stable, partly due to asymptomatic carriers.
  • Immune-mediated nerve damage can occur during or after treatment.

Conclusions:

  • Despite reduced prevalence, leprosy remains a public health concern.
  • Continued vigilance, patient education, and rehabilitation are essential for preventing disability.
  • Accessible patient care and resources are available through US-based programs.